Roca Therapeutics
Created in 2021
Up & running (A)
Existing signals show a regular activitySocial networks
922Activities
Technologies
Entity types
Location
112 Av. Sainte-Marguerite, 06200 Nice, France
Nice
France
Employees
Scale: 2-10
Estimated: 7
SIREN
898778188Engaged catalyst
11
0 0Added in Motherbase
2 years, 2 months ago
Value proposition
A united team creating an innovative therapy to give a new life / vision to patients
First-in-Class Drugs against ocular diseases
driven by hyper-vascularization and chronic inflammation
Revolutionizing severe retinal disease care with topical therapy & saving lives with groundbreaking treatments for uveal melanoma
Created in 2021 and located in Nice (France), Roca Therapeutics is a spin-off from Nice University and SATT Sud Est, incubated by the PACA-Est incubator.
Roca has an internationally recognized team of Directors and Advisors with a strong track record of Translational Research and Drug Development in Oncology, Ophtalmology and Immunology.
Roca Therapeutics is surrounded by several local and national strategic partners: IRCAN, ICN, Centre Antoine Lacassagne, CNRS, University Côte d’Azur, SATT Sud-Est, Canceropole PACA, Incubator Paca-Est, Eurobiomed, ...
Roca Therapeutics has been rewarded by recognized prizes: i-Lab, bpifrance BFTE, PIA3, Amgen Prize, ...
Roca Therapeutics is founded by a lead corporate VC and has been backed by several non-dilutive financings.
In October 2022, Roca Therapeutics completes seed funding round.
Our mission is to revolutionize eye care with innovative, non-invasive treatments, giving patients a brighter, clearer vision of life.
Cancer treatment, Eye disease, Angiogenesis, Inflammation, Drug development, and Personalized therapyOriginal language
A united team revolutionizing therapy to bring patients a new vision of life.
First-in-Class Drugs against ocular diseases
driven by hyper-vascularization and chronic inflammation
Revolutionizing severe retinal disease care with topical therapy & saving lives with groundbreaking treatments for uveal melanoma
Created in 2021 and located in Nice (France), Roca Therapeutics is a spin-off from Nice University and SATT Sud Est, incubated by the PACA-Est incubator.
Roca has an internationally recognized team of Directors and Advisors with a strong track record of Translational Research and Drug Development in Oncology, Ophtalmology and Immunology.
Roca Therapeutics is surrounded by several local and national strategic partners: IRCAN, ICN, Centre Antoine Lacassagne, CNRS, University Côte d’Azur, SATT Sud-Est, Canceropole PACA, Incubator Paca-Est, Eurobiomed, ...
Roca Therapeutics has been rewarded by recognized prizes: i-Lab, bpifrance BFTE, PIA3, Amgen Prize, ...
Roca Therapeutics is founded by a lead corporate VC and has been backed by several non-dilutive financings.
In October 2022, Roca Therapeutics completes seed funding round.
Our mission is to revolutionize eye care with innovative, non-invasive treatments, giving patients a brighter, clearer vision of life.
First-in-Class Drugs against ocular diseases - Roca Therapeutics
First-in-Class Drugs against ocular diseases driven by hyper-vascularization and immuno-suppressive inflammation.A united team creating an innovative therapy to give a new vision to patients.
https://www.roca-therapeutics.org/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
 SATT Sud-Est Research, National and local authorities, Research Services | SATT Sud-Est Research, National and local authorities, Research Services | Other 30 Jan 2025 | | |